Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study

By Reuters News

Oct 19 (Reuters) - Drug developer Veradermics MANE.N said on Monday that its oral pill helped increase hair growth in men with pattern hair loss in a late-stage study.


Here are more details:

  • The company was testing its oral minoxidil formulation, called VDPHL01, in over 500 men with mild-to-moderate pattern hair loss

  • The study met all main and secondary goals showing consistent benefits across patients and strong hair growth, while being generally well tolerated, with no serious side effects linked to the treatment, the company said

  • The oral pill led to superior hair growth compared with placebo after six months

  • The company plans to announce results from another portion of the study later this year

  • "The key push back we hear is around the rationale for using VDPHL01 when inexpensive generic oral minoxidil is widely available. However, with these efficacy data, we believe the commercial case for VDPHL01 is now very strong," said Cantor Fitzgerald analyst Prakhar Agrawal

  • VDPHL01 uses a special extended-release form of minoxidil designed to release the drug slowly over time

  • Minoxidil is currently applied directly to the scalp as a topical treatment for hair loss in men and women

  • Other companies developing novel treatments for hair loss include Pelage Pharmaceuticals and Cosmo Pharmaceuticals

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.